

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**RAJYA SABHA
STARRED QUESTION NO. 123
TO BE ANSWERED ON THE 1ST AUGUST, 2023**

SHORTAGE OF HIV DRUGS

123 SHRI AKHILESH PRASAD SINGH:

Will the Minister of Health and Family Welfare be pleased to state:

- (a) whether it is a fact that there is a nation-wide shortage of the valuable HIV drug Dolutegravir;
- (b) if so, the details thereof and reasons therefor;
- (c) the details regarding the supply and demand of the drug during the last three years, State-wise;
- (d) whether Government has taken any steps to address the shortage of the life-saving drug; and
- (e) if so, the details thereof, and if not, the reasons therefor?

**ANSWER
THE MINISTER OF HEALTH AND FAMILY WELFARE
(DR MANSUKH MANDAVIYA)**

- (a) to (e) A Statement is laid on the Table of the House.

**STATEMENT REFERRED TO IN REPLY TO RAJYA SABHA
STARRED QUESTION NO. 123 * FOR 1ST AUGUST, 2023**

(a) to (e): No, there is no reported nation-wide shortage of Dolutegravir. Dolutegravir (DTG) was introduced under the National AIDS Control Programme (NACP) in a phased manner in 2020.

Dolutegravir is the key Antiretroviral (ARV) medicine prescribed for most People Living with HIV (PLHIV) under the programme.

State-wise details of supply and demand of Dolutegravir (as TLD and single tablet DTG) during the last three years is enclosed in Annexure 1.

Various proactive steps have been undertaken to ensure uninterrupted supply of Antiretroviral (ARV) medicines including Dolutegravir. These measures include strengthening supply chain unit at National level meticulous monitoring of stock at State and facility level as well as ensuring coordination for any emergency relocation. States also authorized to do need-based emergency local procurement of ARV medicine utilising funds allocated under the head “ARV drugs for exceptional cases” and the National AIDS Control Programme Grant-in-aid given to State AIDS Control Societies.

				Annexure 1	
S.No	Name of State	Supply & Demand of TLD in three years (2020-2023)		Supply & Demand of Dolutegravir in three years (2020-2023)	
		Tablet Fixed dose combination TLD (Tenofovir 300 mg +Lamivudine 300mg +Dolutegravir 50mg)		Tablet Dolutegravir (DTG-50mg)	
		Demand	Supply	Demand	Supply
1	Andaman & Nicobar	37,440	46,935	0	255
2	Andhra Pradesh	10,26,18,720	13,88,18,250	36,68,400	38,64,125
3	Arunachal Pradesh	64,080	24,11,265	0	2,580
4	Assam	38,00,160	58,57,305	89,640	1,21,980
5	Bihar	3,68,60,040	4,64,33,550	4,71,600	11,99,095
6	Chandigarh	28,44,900	63,68,835	2,24,640	3,36,315
7	Chhattisgarh	72,61,560	1,15,25,490	1,25,640	4,14,950
8	Delhi	1,59,99,120	2,09,63,460	7,46,640	9,23,865
9	Dadar Nagar Haveli	73,080	1,44,900	2,880	36,010
10	Goa	12,75,300	27,92,145	1,11,960	1,49,400
11	Gujarat	3,67,76,520	4,47,87,930	20,73,600	24,77,770
12	Haryana	1,11,53,700	1,35,98,550	2,64,960	3,81,210
13	Himachal Pradesh	22,43,340	39,38,730	50,760	1,64,865
14	Jammu Kashmir	10,19,880	20,09,415	36,000	1,40,885
15	Jharkhand	58,26,240	75,92,085	69,840	2,19,125
16	Karnataka	6,79,83,120	9,12,43,095	46,53,000	90,40,540
17	Kerala	73,22,580	1,16,60,685	3,50,280	5,38,655
18	Madhya Pradesh	1,50,31,980	2,58,90,540	3,68,280	10,50,295
19	Maharashtra	10,18,35,540	13,36,21,170	49,83,120	98,05,665
20	Manipur	60,44,040	97,29,765	1,75,320	2,42,760
21	Meghalaya	24,34,860	30,81,495	58,320	59,610
22	Mizoram	79,53,120	1,07,37,855	82,800	2,04,035
23	Mumbai	2,12,73,300	2,26,31,820	14,04,000	16,34,310

24	Nagaland	45,74,520	73,68,450	73,440	1,44,735
25	Odisha	77,16,060	1,43,01,480	1,38,240	5,09,920
26	Pondicherry	6,95,520	12,75,825	30,240	18,450
27	Punjab	2,82,75,120	2,86,43,625	2,70,000	6,64,410
28	Rajasthan	2,60,78,580	2,96,00,985	8,90,640	11,14,880
29	Sikkim	62,640	5,78,865	0	3,945
30	Tamil Nadu	6,20,21,520	7,18,98,885	18,60,120	26,10,430
31	Telangana	3,22,73,640	4,71,30,855	7,94,880	15,26,145
32	Tripura	8,58,240	20,65,950	15,480	31,035
33	Uttar Pradesh	6,33,55,680	5,95,18,365	13,06,800	15,24,045
34	Uttarakhand	77,78,160	50,70,705	1,59,120	2,90,600
35	West Bengal	2,29,87,800	3,13,44,195	5,36,400	9,70,705
Total		71,44,10,100	91,46,83,455	2,60,87,040	4,24,17,600

***Demand/Requirement of ARV medicine is calculated based on consumption pattern, changes in programme guidelines and expected increase in patient load. Supply is done as per calculated requirement/demand along with three months' buffer stock.**